Submit Manuscripts
Author Information
Subscribe/Renew
Email Alerts
Feedback
RSS Feed

About the Journal
Editorial Board & Staff

Interventions Homepage Imaging Homepage Interventions Homepage Imaging Homepage

ACC.org
Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions


ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction

ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease
cardiology careers collections past issues search home
     

J Am Coll Cardiol, 1999; 33:2044-2051
© 1999 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olivotto, I.
Right arrow Articles by Cecchi, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olivotto, I.
Right arrow Articles by Cecchi, F.

CLINICAL STUDIES

Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy

Iacopo Olivotto, MD*, Barry J. Maron, MD, FACC{dagger}, Alessio Montereggi, MD*, Francesco Mazzuoli, MD*, Alberto Dolara, MD* and Franco Cecchi, MD*

* Cardiologia di S.Luca and Medicina Generale III, Ospedale di Careggi, Florence, Italy
{dagger} Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA

Manuscript received July 23, 1997; revised manuscript received January 22, 1999, accepted February 12, 1999.

Reprint requests and correspondence: Dr. Barry J. Maron, 920 E. 28th Street, Suite 40, Minneapolis, Minnesota 55407
gencvres{at}skypoint.com


   Abstract
Top
 Abstract
Methods
 Results
 Discussion
 References
 
OBJECTIVES

The present study was designed to prospectively evaluate the prognostic relevance of abnormal blood pressure response to exercise (ABPR), defined as hypotension or failed blood pressure increase (<20 mm Hg) with exercise, in a community-based hypertrophic cardiomyopathy (HCM) population representative of the overall disease spectrum.

BACKGROUND

Abnormal blood pressure response to exercise has been proposed as a marker for hemodynamic instability and increased risk for disease-related mortality in highly selected patient populations with HCM.

METHODS

The study population comprised 126 patients (aged 42 ± 14 years) who underwent maximal symptom-limited cycloergometer exercise testing as part of the standard evaluation at our institution, and who were followed systematically for 4.7 ± 3.7 years after testing.

RESULTS

Of the 126 study patients, 98 (78%) had a normal blood pressure response during exercise, whereas the other 28 (22%) had ABPR, including nine with hypotension and 19 with failed blood pressure rise. During the follow-up period, nine patients (7%) died of HCM-related causes (three suddenly and six heart failure–related), of whom four had ABPR. In those patients aged ≤50 years, survival analysis after exercise testing showed a significantly increased risk for cardiovascular mortality associated with ABPR compared with a normal exercise response (p = 0.04), with an odds ratio of 4.5 (95% confidence interval: 1.1, 20.1). However, ABPR showed low positive predictive accuracy for cardiovascular mortality (i.e., 14%), whereas negative predictive accuracy was high (i.e., 95%).

CONCLUSIONS

A hypotensive blood pressure response during exercise occurred in over 20% of a community-based patient cohort with HCM, and was associated with adverse long-term prognosis in patients <50 years old. However, the positive predictive accuracy of this blood pressure response is too low to justify modifications of clinical management or to allow identification of the high-risk patient based solely on an abnormal test result. By virtue of its high negative predictive accuracy for HCM-related mortality, the blood pressure response to exercise appears to be most valuable (in conjunction with the absence of other well recognized risk factors) as a screening test for the identification of low-risk subsets of patients.

Abbreviations and Acronyms
  ABPR = abnormal blood pressure response to exercise
  ECG = electrocardiogram
  HCM = hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a primary cardiac disease with diverse clinical and genetic expression and varied clinical course (1–11). Many patients experience relatively benign course (12–17), whereas others appear to be at high risk for adverse events and premature death (18–26). A major challenge in the management of the broad HCM disease spectrum has been the identification of subsets of patients predisposed to sudden and unexpected or heart failure–related death (6,7,22,23). Consequently, the risk stratification of patient populations with HCM continues to represent an area of intense investigation, and a number of disease variables have been proposed as risk factors associated with adverse prognosis and increased mortality (2,6–10,20,22–25).

An abnormal systemic blood pressure response to exercise (ABPR) is among those parameters previously considered as a potential marker for hemodynamic instability and increased risk (24,27,28), although its clinical significance and relation to outcome in this disease remains largely unresolved. This variable, like virtually all others previously proposed for HCM, has been tested exclusively in highly selected cohorts from tertiary centers comprising HCM patients referred primarily because they had already been perceived to be at increased risk (12–17,29). Therefore, we have assessed the relevance and clinical implications of an inappropriate blood pressure response to exercise as a risk factor in a large community-based HCM patient population, free of referral bias and therefore more representative of the true disease state.


   Methods
Top
 Abstract
 Methods
Results
 Discussion
 References
 
Patient selection and follow-up.   The clinical features and long-term outcome of HCM in our large cohort of unselected, consecutively studied patients assessed longitudinally in a well defined regional population from the Tuscany region in central Italy have been recently described (14). Between 1983 and 1995, cycloergometer exercise testing was administered in our outpatient clinic as part of the standard evaluation for patients with HCM.

Of the 202 patients in this population, 76 were excluded from the study for the following reasons: severe exercise limitation due to congestive symptoms (New York Heart Association functional class III–IV; n = 19); refusal to comply with the protocol (n = 13); noncardiovascular physical disabilities incompatible with exercise (e.g., severe osteoarthrosis or neurologic deficits; n = 9); age >70 years (n = 8); prior documentation of life-threatening arrhythmias (ventricular fibrillation or sustained ventricular tachycardia; n = 5), and exercise testing performed at other institutions with different methodology and protocol (n = 22). Therefore, the final study group comprised 126 patients (Table 1).


View this table:
[in this window]
[in a new window]
  		Table 1 Demographic, Clinical and Exercise Testing Parameters in 126 Patients With Hypertrophic Cardiomyopathy

 
Mean age at the time of the exercise test was 42 ± 14 years (range 19 to 68); 89 patients were ≤50 years old, and 37 patients were >50 years old. Ninety (71%) were male; 121 patients were in sinus rhythm, whereas the remaining five were in atrial fibrillation. Overall duration of follow-up from the initial diagnosis of HCM was 9.4 ± 6.5 years (range 1 to 29); the follow-up period after the exercise test was 4.7 ± 3.7 years (range 1 to 13).

The diagnosis of HCM in our study patients was based on echocardiographic identification of a hypertrophied and nondilated left ventricle in the absence of another cardiac or systemic disease capable of producing the magnitude of left ventricular hypertrophy evident in that patient (30). No patient identified as having HCM solely in the course of a systematic pedigree analysis was included in the present series (10,20,31); however, 18 patients were evaluated after another relative had become part of the study group. Initial clinical evaluation was taken as the time the diagnosis of HCM was first confirmed. The most recent clinical evaluation was obtained in October to December 1995.

Ages at initial evaluation ranged from 1 to 68 years (mean 36 ± 15); 15 (12%) were <20 years, and four (3%) were >60 years. Ages at the most recent evaluation ranged from 13 to 74 years (mean 47 ± 14). After initial identification, patients were followed in a standard fashion at about one-year intervals with clinical examination, two-dimensional echocardiogram, 12-lead electrocardiogram (ECG) and 24- or 48-h ambulatory (Holter) ECG.

Exercise testing.   Patients had cardioactive medications withdrawn at least five half-lives before the exercise test, with the exception of the 12 patients receiving amiodarone; each fasted ≥4 h before the test. Maximum, symptom-limited exercise tests were performed on a bicycle ergometer (Quinton Q 2000, Seattle, Washington) in the upright position. The same protocol was used with all patients, with an initial workload of 25 W, stepwise workload increments of 25 W every 3 min and a recovery phase comprising 3 min against a workload of 25 W followed by another 3 min at 0 W. Three leads were monitored in a continuous fashion (D2, V2 and V5); in addition, a 12-lead ECG was recorded at baseline, and at each minute during exercise and the recovery phase. Blood pressure was measured using a mercury sphygmomanometer at baseline, at 60 and 150 s of each step, and every minute during the recovery phase. Maximum predicted heart rate and workload for each patient was calculated with respect to age, gender, height and weight (32). Percent of functional capacity was calculated as: (maximum workload performed/maximum predicted workload) x 100.

An abnormal blood pressure response to exercise was defined as follows: 1) exercise-induced hypotension; any decrease in systolic blood pressure below baseline values occurring during the exercise phase or recovery in the absence of an initial rise with exercise, or alternatively a sustained (>1 min in duration) decrease of ≥20 mm Hg during exercise after an initial rise, and 2) failure to increase blood pressure with exercise, defined as a systolic blood pressure rise of less than 20 mm Hg from baseline during exercise.

Echocardiography.   Echocardiographic studies were performed using commercially available instruments (Toshiba 65A and 270) and 3.5- or 5.0-mHz transducers. Extent and distribution of left ventricular hypertrophy was assessed from the two-dimensional echocardiogram as previously described (33,34). Magnitude of the peak instantaneous left ventricular outflow tract gradient under basal conditions was estimated with continuous wave Doppler (35). Significant left ventricular outflow tract obstruction was considered present when the peak instantaneous gradient was ≥30 mm Hg.

Statistical analysis.   Data were expressed as mean ± standard deviation. Statistical analyses were performed using unpaired Student t test for the comparison of normally distributed data. Chi-square test was used to compare noncontinuous variables expressed as proportions. Univariate analyses for survival curves were calculated using Kaplan-Meier estimates (36). Univariate and multivariate regression analysis, for the identification of independent predictors of HCM-related death, were performed by the Cox regression model (37), using a SPSS statistical package (SPSS, Chicago, Illinois). The multivariate analysis used the forced entry method, and only included those demographic, clinical and echocardiographic variables that were significantly associated with HCM-related mortality at univariate analysis.


   Results
Top
 Abstract
 Methods
 Results
Discussion
 References
 
Exercise testing.   The 126 study patients exercised for 12 ± 4 min (range 2 to 25), reaching maximum workloads varying from 25 to 225 W; percent of maximum predicted heart rate achieved was 87 ± 14%; mean percent of predicted functional capacity was 75 ± 23% (Table 1). Reasons for termination of the test were as follows: fatigue (67 patients; 53%), dyspnea (26 patients; 21%), chest pain (21 patients; 16%), symptomatic hypotension (7 patients; 6%) and arrhythmias (5 patients; 4%). In 104 patients, ≥75% of the predicted maximal heart rate value was achieved during exercise, whereas in the other 22 patients testing was terminated before such levels could be achieved. Complete exercise test results for the study group are shown in Table 1.

During the exercise test, 33 patients (26%) had arrhythmias, including 29 with multiple ventricular premature beats, 2 with paroxysmal atrial fibrillation and 1 each with nonsustained ventricular tachycardia or nonsustained supraventricular tachycardia. In four patients exercise testing elicited rate-dependent conduction defects (complete or incomplete left bundle branch block) that had been absent at rest, whereas 23 others had ST-segment and T-wave alterations, including 16 patients in whom ST-segment depression suggested myocardial ischemia (i.e., ≥2 mm).

Systemic blood pressure response to exercise.   Of the 126 patients, 98 (78%) showed normal blood pressure increase during the exercise test (mean 60 ± 25 mm Hg; range 25 to 110) (Table 1). The remaining 28 (22%) had an ABPR, including 19 patients in whom blood pressure failed to increase appropriately (maximum increase 10 ± 6 mm Hg; range 5 to 18), and nine others with hypotension (maximum blood pressure drop 28 ± 6 mm Hg; range –20 to –35); six of these nine had an initial blood pressure rise followed by subsequent drop ≥20 mm Hg, whereas the other three had blood pressure drop below baseline values in the absence of an initial rise (Fig. 1; Table 2). Patients with ABPR more frequently experienced dizziness during the exercise test than patients with a normal blood pressure response (25% vs. 2%, p < 0.001; Table 1), but there were no other significant differences between the two groups with regard to the occurrence of symptoms and arrhythmias (Table 1).



View larger version (51K):
[in this window]
[in a new window]
  		Figure 1 Diagram showing systolic blood pressure (BP) and heart rate responses during exercise and the recovery phase in a severely symptomatic 16-year old girl with nonobstructive hypertrophic cardiomyopathy (patient #1 in Table 2). Systolic blood pressure failed to increase from the baseline value of 100 mm Hg, and the test was interrupted after 2 min and 30 s due to hypotension (baseline systolic blood pressure of 100 mm Hg dropping abruptly to 80 mm Hg) associated with dizziness. This patient died suddenly and unexpectedly six months after the exercise test.

 

View this table:
[in this window]
[in a new window]
  		Table 2 Clinical and Demographic Features of 28 Patients With Hypertrophic Cardiomyopathy and Abnormal Systemic Blood Pressure Response to Exercise

 
Compared with patients with normal blood pressure response, the 28 patients with ABPR achieved a lesser degree of cardiovascular stress as judged by maximum heart rate and double product values (Table 1). Patients with ABPR were also younger and more often female, had smaller left ventricular end-diastolic dimension and more often experienced chest pain unrelated to exercise testing. The patient subgroups with and without ABPR did not differ in terms of the frequency of drug treatment with amiodarone, beta-adrenergic blocking agents, calcium channel antagonists, angiotensin-converting enzyme inhibitors or diuretics during the follow-up period (Table 1).

Peak systolic left ventricular outflow tract gradient (≥30 mm Hg; range 30 to 110 mm Hg) measured by Doppler echocardiography under basal conditions before exercise testing was present in 26 of the 126 study patients. Outflow gradients ≥30 mm Hg were present with similar frequency in patients with ABPR (9/28; 32%) and those with normal pressure response to exercise (18/98; 18%; p = NS) (Table 1). Average outflow tract gradient was also similar in the two patient subgroups (28 ± 34 mm Hg with ABPR vs. 32 ± 26 mm Hg without ABPR; p = NS).

Cardiovascular mortality and predictive value of abnormal blood pressure response.   During the follow-up period, nine patients died of HCM-related causes, at 17 to 69 years of age (mean 43 ± 18). Duration of time between the exercise test and death was 5.6 ± 3.1 years (range, 5 months to 8 years). Of the 9 HCM-related deaths, six were primarily heart failure–related and three were sudden and unexpected. Of the 6 patients who died of heart failure, 2 had ABPR (one with hypotension and one with failure to appropriately increase blood pressure). Three patients died suddenly, each before the age of 30; two of these patients had ABPR, manifested by symptomatic exercise-induced hypotension in both cases (Table 1; Fig. 1). Therefore, of the 9 patients with HCM-related death, a total of 4 (44%) had ABPR.

Of the other 117 surviving patients, a total of 24 (20%) had ABPR, of whom six had exercise-induced hypotension and 18 failed to appropriately increase blood pressure. The negative predictive accuracy of ABPR for cardiovascular mortality was 95% and positive predictive accuracy was 14%.

In the subset of patients aged 50 or less at the time of the exercise test (n = 89), Kaplan-Meier survival analysis showed an increased risk for HCM-related mortality in patients with ABPR as compared with those patients with a normal blood pressure response to exercise (p = 0.04; Fig. 2). Conversely, in those patients >50 years of age (n = 37), ABPR was not associated with an increased risk for cardiovascular mortality (p = 0.4). Only one of the nine HCM-related deaths occurred among patients >50 years of age (in a 68-year-old man with a normal blood pressure response during exercise), whereas the remaining eight deaths occurred among patients ≤50 years. The two subgroups of patients, aged >50 years and ≤50 years at the time of the exercise test, had a similar prevalence of ABPR (24% vs. 19%, respectively; p = NS), and comparable follow-up duration (4.5 ± 3.6 years vs. 3.7 ± 2.9 years, respectively; p = NS).



View larger version (14K):
[in this window]
[in a new window]
  		Figure 2 Cumulative survival measured from the time of the maximal symptom-limited exercise test in 89 hypertrophic cardiomyopathy patients aged ≤50 years. The 21 patients who demonstrated abnormal systemic blood pressure response to exercise (ABPR; broken line) showed significantly reduced survival compared with the 68 patients with a normal blood pressure (BP) response (solid line), over an average follow-up period of 4.7 ± 3.7 years.

 
Univariate regression analysis showed only ABPR, age, history of syncope and atrial fibrillation, out of 20 demographic, clinical and echocardiographic features (Table 1), to be significantly associated with HCM-related mortality in patients ≤50 years of age. Of these four variables, the only independent predictors of risk at multivariate analysis were ABPR (p = 0.04; odds ratio = 4.5; 95% confidence interval: 1.1, 20.1) and atrial fibrillation (p = 0.03; odds ratio = 5.4; 95% confidence interval: 1.1, 7.5). For those patients ≤50 years of age, negative predictive accuracy of ABPR for cardiovascular mortality was 94% and positive predictive accuracy was 19%. The presence of nonsustained ventricular tachycardia on Holter ECG monitoring was not significantly associated with HCM-related mortality in our study population at univariate analysis (p = 0.4), and therefore was not included in the multivariate model.


   Discussion
Top
 Abstract
 Methods
 Results
 Discussion
References
 
Risk stratification in HCM.   Sudden and unexpected death, the most devastating feature of the natural history of HCM, is a relatively uncommon event, but may constitute the first clinical manifestation of the disease in previously asymptomatic patients (1–7,18,19,22–26). Despite extensive efforts over three decades, the assessment of high (and low) risk in individual patients with HCM remains largely unresolved (6,7) due to the relatively low prevalence of the disease, extreme heterogeneity and complex pathophysiology characteristic of the disease, as well as the severe degree to which tertiary center patient referral bias has dominated the HCM literature and has skewed our perceptions of this condition (6,7,29). A hypotensive blood pressure response to exercise has been regarded as evidence for hemodynamic instability and proposed as a marker of increased risk for adverse cardiovascular events and mortality, both in coronary artery disease (38–41) and in selected tertiary center patient populations with HCM (24,27,28). For these reasons, we have investigated the clinical implications of the systemic blood pressure response to exercise in a large community-based HCM cohort in which the selection of patients was not biased by the preferential referral of those already judged to be at high risk.

Prevalence of ABPR.   In our community-based outpatient population, exercise testing was administered as a part of a standard noninvasive evaluation of patients with HCM. Of the 126 patients in the study group, about 20% showed an ABPR that included the development of hypotension or the failure to appropriately increase blood pressure with exercise. The prevalence of ABPR in the present study patients was similar, although somewhat lower, than that previously reported by Frenneaux et al. (28) (i.e., 22% vs. 33%). These differences may be explained by the fact that the latter study used treadmill exercise testing (rather than cycloergometer) and probably comprised higher risk patients. Compared with those patients with a normal blood pressure response to exercise, patients with ABPR were also younger, more often experienced chest pain, had smaller left ventricular cavity size, and reached a lower degree of cardiovascular stress, as judged by the maximum double product achieved.

Hypertrophic cardiomyopathy–related mortality and ABPR.   In our study, ABPR was associated with HCM-related death in patients ≤50 years, at the time of the exercise test, but was not a predictor of mortality in those patients >50 years. Among our study patients, only one of the nine HCM-related deaths occurred in patients >50 years of age, consistent with reports that HCM diagnosed later in life is usually associated with a benign prognosis (6,7). Thus, the survival analysis in the present study specifically describes that subset of HCM patients for whom risk stratification is most appropriate, that is, those ≤50 years. In the follow-up period subsequent to the exercise test, patients aged ≤50 years with ABPR showed a fourfold increase in premature HCM-related cardiovascular mortality (either suddenly or due to heart failure), compared with those with a normal blood pressure rise. However, the positive predictive accuracy of ABPR for mortality was low (i.e., 14%). This lack of predictability appears in large measure to be a consequence of the relatively uncommon occurrence of HCM-related death in our cohort, as reflected by the wide confidence interval evident in the multivariate survival analysis. Moreover, the uncertain significance of ABPR as a marker for the subsequent occurrence of clinical events is underlined by the fact that of the three patients in our study population who ultimately died suddenly, none collapsed during or just after exercise. Consequently, although we established a relationship between ABPR and increased cardiovascular mortality in patients ≤50 years of age, the positive predictive value of this single test is itself too low to allow identification of the high risk patient or modify clinical decision making. These observations substantiate the prior difficulties, shared by many authors, in defining subgroups of high risk HCM patients (2,6–10,20,22–25).

Identification of low risk patients.   Conversely, ABPR showed a negative predictive accuracy of 95% for HCM-related mortality. This finding has important clinical implications because a normal blood pressure response during exercise testing appears to reliably identify those patients at lower risk. Therefore, as with other tests that have been proposed for risk stratification in patients with HCM (such as Holter ambulatory ECG) (23,25), assessment of the blood pressure response to exercise appears to be most useful as a screening study and an aid in identifying low risk subsets of HCM patients; indeed, such individuals are probably most patients within the overall HCM population (6). In this regard, a normal blood pressure response to exercise associated with the absence of certain acknowledged risk factors—previous cardiac arrest or sustained ventricular tachycardia, family history of multiple sudden or other HCM-related deaths and malignant genotype, multiple-repetitive or prolonged bursts of nonsustained ventricular tachycardia on ambulatory Holter ECG, recurrent syncope and probably massive left ventricular hypertrophy (wall thickness ≥35 mm)—would appear to define those patients at low risk for an adverse clinical event, as suggested by Spirito et al. (6). Such patients probably do not require further aggressive diagnostic or therapeutic interventions and benefit most from reassurance regarding their prognosis (6,7).

Mechanisms and study limitations.   The different prognostic implications of ABPR in HCM patients >50 years and ≤50 years may be the consequence of diverse underlying mechanisms in the two age groups. In younger patients, ABPR may reflect hemodynamic instability and thus suggest risk for a sudden cardiac event; however, in older patients, ABPR may simply reflect age-related cardiovascular changes which have little prognostic relevance. The mechanisms that may explain the abnormal pressure response to exercise in younger patients with HCM include: 1) impaired left ventricular filling secondary to tachycardia, associated with an inability to maintain an adequate stroke volume; or 2) an exaggerated fall in peripheral vascular resistance related to an abnormal ventricular mechanoceptor reflex, resulting in an inhibition of sympathetic tone in resistance vessels (28).

Exercise testing conducted in this large study population was used primarily as part of the clinical evaluation in an outpatient setting. Therefore, invasive hemodynamic measurements were impractical for our study patients, prohibiting a direct assessment of peripheral vascular resistance, cardiac output and consequently the precise physiologic mechanisms responsible for ABPR. A second limitation results from the small number of sudden cardiac deaths that occurred during the follow-up period. This low event rate probably reflects the relatively benign prognosis of HCM in our community-based cohort, as well as the administration of amiodarone to a sizeable subset of our patients. As a consequence, although ABPR proved to be an independent risk factor for combined sudden and heart failure-related HCM deaths in patients ≤50 years of age, we could not assess the prognostic significance of ABPR with regard to sudden and unexpected death alone.


   References
Top
 Abstract
 Methods
 Results
 Discussion
 References
 

  1. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelation of clinical manifestations, pathophysiology, and therapy. N Engl J Med 1987;316:780–9, 844–52.
  2. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol. 1981;47:532–538[CrossRef][Medline]
  3. Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. Circulation. 1968;37:759–788[Abstract/Free Full Text]
  4. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy: a review. Prog Cardiovasc Dis. 1985;28:1–83[CrossRef][Medline]
  5. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation. 1995;92:1680[Free Full Text]
  6. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775–785[Free Full Text]
  7. Maron BJ. Hypertrophic cardiomyopathy. Lancet. 1997;350:127–133[CrossRef][Medline]
  8. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation. 1995;92:1336–1347[Free Full Text]
  9. Schwartz K, Carrier L, Guicheney P, Komajda M. Molecular basis of familial cardiomyopathies. Circulation. 1995;91:532–540[Free Full Text]
  10. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and {alpha}-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332:1058–1064[Abstract/Free Full Text]
  11. Louie EK, Edwards LC. Hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 1994;36:275–308[Medline]
  12. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med. 1989;320:749–755[Abstract]
  13. Kofflard MJ, Waldstein DJ, Vos J, ten Cate FJ. Prognosis in hypertrophic cardiomyopathy: long-term follow-up in a large, unselected outpatient population. Am J Cardiol. 1993;72:939–943[CrossRef][Medline]
  14. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected population. J Am Coll Cardiol. 1995;26:1529–1536[Abstract]
  15. Shapiro LM, Zezulka A. Hypertrophic cardiomyopathy: a common disease with a good prognosis—five year experience of a district general hospital. Br Heart J. 1983;50:530–533[Abstract/Free Full Text]
  16. Cannan CR, Reeder GS, Bailey KR, Melton LJ III, Gersh BJ. Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990. Circulation. 1995;92:2488–2495[Abstract/Free Full Text]
  17. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650–5.
  18. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: profile of 78 patients. Circulation. 1982;65:1388–1394[Abstract/Free Full Text]
  19. Swan DA, Bell B, Oakley C, Goodwin J. Analysis of symptomatic course and prognosis and treatment of hypertrophic obstructive cardiomyopathy. Br Heart J. 1971;33:671–685[Free Full Text]
  20. Watkins H, Rosenzweig A, Hwang D-S, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108–1114[Abstract]
  21. Anan R, Greve G, Thierfelder L, et al. Prognostic implication of novel ß cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest. 1994;93:280–285[Medline]
  22. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy: assessment of patients at high risk. Circulation. 1989;80:1489–1492[Free Full Text]
  23. Maron BJ, Cecchi F, McKenna WJ. Risk factors and current status of risk stratification profiles for sudden cardiac death in patients with hypertrophic cardiomyopathy. Br Heart J. 1994;72(Suppl):S14–S18
  24. Sadoul N, Prasad K, Elliot PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96:2987–2991[Abstract/Free Full Text]
  25. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley CM, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy: I. Influence on prognosis. Br Heart J. 1981;46:168–172[Abstract/Free Full Text]
  26. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol. 1989;13:1283–1288[Abstract]
  27. Edwards RHT, Krisinsson A, Warrel DA, Goodwin JF. Effects of propranolol on response to exercise in hypertrophic cardiomyopathy. Br Heart J. 1970;32:219–225[Abstract/Free Full Text]
  28. Frenneaux MP, Counihan PJ, Caforio ALP, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation. 1991;82:1995–2002
  29. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol. 1993;72:970–972[CrossRef][Medline]
  30. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol. 1979;43:1242–1244[CrossRef][Medline]
  31. Maron BJ, Nichols PF, Pickle LW, Wesley YE, Mulvihill JJ. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol. 1984;53:1087–1094[CrossRef][Medline]
  32. Wasserman K, Hansen JE, Sue DY, Whipp BJ. Principles of Exercise Testing and Interpretation. Philadelphia: Lea & Fabiger; 1987.
  33. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide angle, two-dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981;48:418–428[CrossRef][Medline]
  34. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26:1699–1708[Abstract]
  35. Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler in noninvasive assessment of the left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;19:91–99[Abstract]
  36. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481[CrossRef]
  37. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–220
  38. Dubach P, Froelicher VF, Klein J, Oakes D, Grover-McKay M, Friis R. Exercise-induced hypotension in a male population. Criteria, causes and prognosis. Circulation. 1988;78:1380–1387[Abstract/Free Full Text]
  39. Hammermeister KE, DeRouen TA, Dodge HT, Zia M. Prognostic and predictive value of exertional hypotension in suspected coronary artery disease. Am J Cardiol. 1983;51:1261–1265[CrossRef][Medline]
  40. Weiner DA, McCabe CH, Cutler SS, Ryan TJ. Decrease in systolic blood pressure during exercise testing: reproducibility, response to coronary bypass surgery and prognostic significance. Am J Cardiol. 1982;49:1627–1631[CrossRef][Medline]
  41. San Marco ME, Pontius S, Selvester RH. Abnormal blood pressure response and marked ischemic ST depression as predictors of severe coronary artery disease. Circulation. 1980;61(Suppl III):III-572–III-578



This article has been cited by other articles:


Home page
 HeartHome page
K Sakata, H Ino, N Fujino, M Nagata, K Uchiyama, K Hayashi, T Konno, M Inoue, H Kato, Y Sakamoto, et al.
Exercise-induced systolic dysfunction in patients with non-obstructive hypertrophic cardiomyopathy and mutations in the cardiac troponin genes
Heart, October 1, 2008; 94(10): 1282 - 1287.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
P Elliott and P Spirito
Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice
Heart, October 1, 2008; 94(10): 1269 - 1275.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
K Prasad, L Williams, R Campbell, P M Elliott, W J McKenna, and M Frenneaux
Episodic syncope in hypertrophic cardiomyopathy: evidence for inappropriate vasodilation
Heart, October 1, 2008; 94(10): 1312 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. Sen-Chowdhry and W. J. McKenna
Non-invasive risk stratification in hypertrophic cardiomyopathy: don't throw out the baby with the bathwater
Eur. Heart J., July 1, 2008; 29(13): 1600 - 1602.
[Full Text] [PDF]

Home page
 EuropaceHome page
L. Williams and M. Frenneaux
Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment
Europace, September 1, 2007; 9(9): 817 - 822.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Thaman, P. M. Elliott, J. S. Shah, B. Mist, L. Williams, R. T. Murphy, W. J. McKenna, and M. P. Frenneaux
Reversal of Inappropriate Peripheral Vascular Responses in Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol., September 6, 2005; 46(5): 883 - 892.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M. P Frenneaux
Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy
Heart, May 1, 2004; 90(5): 570 - 575.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
K. Toiyama, I. Shiraishi, T. Oka, A. Kawakita, N. Iwasaki, T. Tanaka, K. Sakata, T. Itoi, K. Shuntoh, M. Yamagishi, et al.
Assessment of coronary flow reserve with a Doppler guide wire in children with tetralogy of Fallot before and after surgical operation
J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1195 - 1197.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1687 - 1713.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
Eur. Heart J., November 1, 2003; 24(21): 1965 - 1991.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
I. Olivotto, R. Gistri, P. Petrone, E. Pedemonte, D. Vargiu, and F. Cecchi
Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy
J. Am. Coll. Cardiol., January 15, 2003; 41(2): 315 - 321.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
Q. Ciampi, S. Betocchi, R. Lombardi, F. Manganelli, G. Storto, M. A. Losi, E. Pezzella, F. Finizio, A. Cuocolo, and M. Chiariello
Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy
J. Am. Coll. Cardiol., July 17, 2002; 40(2): 278 - 284.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
B. J. Maron
Hypertrophic Cardiomyopathy: A Systematic Review
JAMA, March 13, 2002; 287(10): 1308 - 1320.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
H. Kuhn, F. Gietzen, and C. Leuner
'The abrupt no-flow': a no-reflow like phenomenon in hypertrophic cardiomyopathy
Eur. Heart J., January 1, 2002; 23(1): 91 - 93.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al.
Task Force on Sudden Cardiac Death of the European Society of Cardiology
Eur. Heart J., August 2, 2001; 22(16): 1374 - 1450.
[PDF]

Home page
 Eur Heart JHome page
B.J. Maron
Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator
Eur. Heart J., December 2, 2000; 21(24): 1979 - 1983.
[PDF]

Home page
 J Am Coll CardiolHome page
P. M. Elliott, J. Poloniecki, S. Dickie, S. Sharma, L. Monserrat, A. Varnava, N. G. Mahon, and W. J. McKenna
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients
J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2212 - 2218.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R.C. Saumarez and A.A. Grace
Paced ventricular electrogram fractionation and sudden death in hypertrophic cardiomyopathy and other non-coronary heart diseases
Cardiovasc Res, July 1, 2000; 47(1): 11 - 22.
[Full Text] [PDF]

Home page
 NEJMHome page
B. J. Maron, W.-K. Shen, M. S. Link, A. E. Epstein, A. K. Almquist, J. P. Daubert, G. H. Bardy, S. Favale, R. F. Rea, G. Boriani, et al.
Efficacy of Implantable Cardioverter-Defibrillators for the Prevention of Sudden Death in Patients with Hypertrophic Cardiomyopathy
N. Engl. J. Med., February 10, 2000; 342(6): 365 - 373.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire